Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)

Part of paid clinical trials in Houston, Texas.

Sponsor
Tarsus Pharmaceuticals, Inc.
Study ID
NCT07443202
Phase
PHASE2
Status
Enrolling By Invitation

Conditions

  • Ocular Rosacea

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • lotilaner — DRUG
    lotilaner
  • Vehicle — DRUG
    Vehicle of lotilaner

Study Details

To evaluate lotilaner treatment in patients with ocular rosacea.

Key Dates

Start date
Dec 5, 2025
Status verified
Feb 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2027

Study Design

Enrollment
155 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment arm
    lotilaner - high dose and low dose
  • Other: Control arm
    Vehicle of lotilaner - high dose and low dose

Primary Outcome Measure

Incidence of Treatment Emergent Adverse Events [ Time Frame: Week 16 ]

Locations (2)

FacilityCityStateZIPSite coordinators
SiteHoustonTexas77027-
SiteLynchburgVirginia24502-

Find similar trials in Houston, TX

By research site
Site· Houston, TXSite· Lynchburg, VA